A
Anders Ellekær Junker
Researcher at University of Copenhagen
Publications - 26
Citations - 1277
Anders Ellekær Junker is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Fatty liver & Type 2 diabetes. The author has an hindex of 9, co-authored 17 publications receiving 1039 citations. Previous affiliations of Anders Ellekær Junker include Copenhagen University Hospital & Steno Diabetes Center.
Papers
More filters
Journal ArticleDOI
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
TL;DR: Evidence is provided that treatment with GLP-1R agonists leads to weight loss in overweight or obese patients with or without type 2 diabetes mellitus.
Journal ArticleDOI
Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease.
Lili Niu,Lili Niu,Philipp E. Geyer,Philipp E. Geyer,Nicolai J. Wewer Albrechtsen,Lise Lotte Gluud,Alberto Santos,Sophia Doll,Sophia Doll,Peter V. Treit,Jens J. Holst,Filip K. Knop,Filip K. Knop,Tina Vilsbøll,Tina Vilsbøll,Anders Ellekær Junker,Anders Ellekær Junker,Stephan Sachs,Kerstin Stemmer,Timo D. Müller,Matthias H. Tschöp,Susanna M. Hofmann,Matthias Mann,Matthias Mann +23 more
TL;DR: Plasma proteome profiling can identify potential biomarkers and drug targets in liver disease and strongly associated DPP4, ANPEP, TGFBI, PIGR, and APOE with NAFLD and cirrhosis.
Journal ArticleDOI
Comparison of Paclitaxel- and Sirolimus-Eluting Stents in Everyday Clinical Practice: The SORT OUT II Randomized Trial
Anders Galløe,Leif Thuesen,Henning Kelbæk,P Thayssen,Klaus Rasmussen,Peter Riis Hansen,Niels Bligaard,Kari Saunamäki,Anders Ellekær Junker,Jens Aarøe,Ulrik Abildgaard,Jan Ravkilde,Thomas Engstrøm,Jan Skov Jensen,Henning Rud Andersen,Hans Erik Bøtker,Søren Galatius,Steen Dalby Kristensen,Jan Madsen,Lars Romer Krusell,Steen Z. Abildstrom,Ghita B. Stephansen,Jens Flensted Lassen +22 more
TL;DR: In this practical randomized trial, there were no significant differences in clinical outcomes between patients receiving sirolimus- and paclitaxel-eluting stents.
Journal ArticleDOI
Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia
TL;DR: It is concluded that patients with histologically verified nonalcoholic fatty liver disease (NAFLD) have an impaired incretin effect and hyperglucagonaemia.
Journal ArticleDOI
Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes.
Nicolai J. Wewer Albrechtsen,Anders Ellekær Junker,Mette Christensen,Sofie Hædersdal,Flemming Wibrand,Allan M. Lund,Katrine D. Galsgaard,Jens J. Holst,Filip K. Knop,Tina Vilsbøll +9 more
TL;DR: Elevated plasma levels of total amino acids associate with hyperglucagonemia in NAFLD patients independently of glycemic control, BMI or cholesterol - supporting the potential importance of a "liver-α-cell axis" in which glucagon regulates hepatic amino acid metabolism.